Spero Therapeutics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Esther Rajavelu
- Full Time Employees
- 25
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 675 Massachusetts Avenue Cambridge MA United States 02139
- IPO Date
- Nov 2, 2017
- CIK
- 0001701108
- Website
- sperotherapeutics.com
- Similar Companies
- Business
- Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel treatments for rare diseases and serious bacterial infections caused by multi-drug resistant (MDR) Gram-negative pathogens. The company's core product candidates include tebipenem HBr, an investigational oral carbapenem antibiotic targeting complicated urinary tract infections (cUTI) including acute pyelonephritis, intended as an effective outpatient oral therapy alternative to intravenous treatments; and SPR720, a prodrug antibiotic developed for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, which the company discontinued in 2025 following a review of clinical data. Spero also focuses on other pipeline programs addressing MDR bacterial infections through innovative mechanisms aimed at reducing virulence and persistence of pathogens such as Pseudomonas aeruginosa. Founded in 2014 and headquartered in Cambridge, Massachusetts, Spero Therapeutics operates primarily in the United States with strategic partnerships and licensing agreements extending its geographic reach. A significant recent development includes its collaboration with GlaxoSmithKline (GSK), which acquired exclusive rights outside certain Asian territories for tebipenem HBr in 2022, with plans to commercialize the product globally. In 2025, the Phase 3 PIVOT-PO trial for tebipenem HBr was stopped early due to meeting primary efficacy endpoints, demonstrating non-inferiority to intravenous imipenem-cilastatin in hospitalized patients with cUTI. This trial success positions tebipenem HBr for an anticipated FDA submission in the fourth quarter of 2025 and potential regulatory approval by the second half of 2026, marking a critical strategic milestone for Spero. The company has since discontinued development of SPR720 but continues to focus on advancing tebipenem HBr and its broader pipeline of treatments addressing antibiotic resistance challenges. Spero Therapeutics’ strategic direction emphasizes advancing oral antibiotic therapies for difficult-to-treat infections, leveraging partnerships for regulatory and commercial support while maintaining a pipeline of early-stage and clinical-stage assets targeting high unmet medical needs. The company is publicly traded under the ticker symbol SPRO on the NASDAQ and maintains a strong cash position to support its clinical development and operational activities. Its operational strategy combines proprietary research with collaborative development to drive innovation in anti-infective therapies. This description encompasses Spero Therapeutics’ current business focus, product portfolio including tebipenem HBr and discontinued SPR720, recent strategic partnership with GSK, clinical trial progress, and financial positioning as of late 2025. Sources confirm the Phase 3 trial achievements, partnership details, pipeline updates, and strategic shifts within the last two years.
Company News
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Russian plague outbreak could boost these under-the-radar pharma stocks
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics Q2 Earnings Call Highlights
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)